SummaryThis is a single arm study. Eligible participants will receive durvalumab (immunotherapy) at the same time as 4-cycles of cisplatin/carboplatin and etopside chemotherapy, which will be given as an intravenous infusion every three weeks for up to 12 weeks. Maintenance therapy with durvalumab will continue for 4 weeks once the chemotherapy cycles have been completed, until there is evidence of disease progression. Participants will also receive 10 chest radiotherapy sessions, which will take approx. 2 weeks to complete (given either concurrently with cycle 3 or 4 of chemotherapy (called concurrent radiotherapy) or within 6 weeks of finishing chemotherapy (called consolidation radiotherapy). Participants will be monitored throughout the study, for any adverse events or for progression of disease.
Use the hyperlinks, where available to access additional clinical trial information.
A phase II study of platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first line treatment of patients with extensive-stage small-cell lung cancer